Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Azelnidipine

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Rezaltas

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Rezaltas

    Azelnidipine

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Rezaltas

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Azelnidipine

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2020 Revenue in Millions : 123

    2019 Revenue in Millions : 137

    Growth (%) : -11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Rezaltas

    Azelnidipine

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Rezaltas

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Azelnidipine

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2021 Revenue in Millions : 104

    2020 Revenue in Millions : 122

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Rezaltas

    Azelnidipine

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Rezaltas

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Azelnidipine

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2019 Revenue in Millions : 139

    2018 Revenue in Millions : 148

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF